Format
Tablet Supplements: Formulation, Compression and Manufacturing
A tablet must combine dose, powder behaviour, compressibility, mechanical strength and disintegration in a manufacturable unit. The process route follows the formulation—not the other way around.
Short answer
A tablet is a compressed unit dose whose ingredients and process must produce consistent weight and composition, adequate strength, acceptable disintegration or release, and a usable size. Direct compression is attractive when the blend already flows and compacts well; granulation may be needed when it does not.
Harder is not automatically better. More compression can improve mechanical strength while reducing porosity and changing disintegration or dissolution. Tablet development is therefore a balance between formulation, process and performance.
Evidence guide: Published evidence — supported by the linked technical source. · Development guidance — a practical way to frame or test the product, not a universal specification. · Manufacturer-specific — depends on the selected process, equipment and commercial arrangement. · Product-specific validation — must be demonstrated with the actual formula, process, pack and market.
Tablet architecture
A supplement tablet may include:
| Component | Main job | Development question |
|---|---|---|
| Functional ingredients | Deliver the intended specification | Dose, particle properties, stability, compatibility |
| Filler/diluent | Builds mass and supports processing | Compressibility, density and product size |
| Binder | Helps particles form a coherent tablet | Strength versus disintegration |
| Disintegrant | Helps the tablet break up in the intended medium | Type, level and process sensitivity |
| Lubricant | Reduces friction during compression/ejection | Overmixing or excess can affect bonding/wetting |
| Glidant | Supports powder flow | Must suit the blend and process |
| Coating system, if used | Appearance, handling, taste or protection | Process, stability and performance implications |
Not every formula needs every category, and excipient function can overlap.
Direct compression or granulation?
Direct compression generally involves blending a suitable powder system and compressing it without an intermediate granulation step. It is operationally simpler, but the materials must provide adequate flow, die filling, content uniformity, compactability and ejection.
Granulation enlarges or structures particles before compression. Wet granulation can improve flow and distribution but introduces liquid and drying. Dry granulation avoids a liquid addition but applies compaction and milling. Either route can change particle and tablet behaviour.
Published literature describes all three as established routes. It does not justify selecting one without product data. Continue with tablet formulation and the manufacturing process guide for the decision points.
Active loading and tablet size
A high active fraction can leave less room for materials that support flow, binding, disintegration and lubrication. But a low active fraction can create a different problem: distributing a small dose uniformly through a larger blend.
Tablet weight, shape and tooling determine dimensions together with material density and compression. The product team should evaluate:
- required raw-material mass per serving;
- one versus multiple tablets;
- swallowability and edge profile;
- score lines only where technically and legally appropriate;
- tooling availability and manufacturer capability;
- coating weight and final dimensions.
Do not promise a small tablet before reconciling the complete formulation mass.
Hardness, friability and disintegration
These attributes interact but are not interchangeable.
- Mechanical strength or tensile strength helps the tablet withstand downstream handling.
- Friability assesses a form of abrasion/chipping risk under a defined test.
- Disintegration measures tablet break-up under a defined method.
- Dissolution, where relevant, evaluates release into solution and is not proven by disintegration alone.
Compression force, formulation and process history influence tablet pore structure and bonding. A tablet can be strong yet fail the intended disintegration target, or disintegrate rapidly but be too fragile for coating and packing. Specifications should be product-appropriate and validated.
Coating is a separate system
Coating may support appearance, swallowability, taste management, handling or environmental protection. It adds formulation and process requirements: coating composition, weight gain, spray rate, atomization, inlet/exhaust conditions, curing where relevant and compatibility with the core.
A cosmetic film coat should not be described as an enteric or modified-release system. Functional-release coatings require specialized development and evidence. Even a conventional coat can affect disintegration and stability, so test the finished coated tablet rather than relying only on core results.
Stability and packaging
Tablets can be affected by moisture, oxygen, light, heat and physical abrasion. The risk depends on actives, excipients, coating and process.
Bottle packs may need closure, seal, headspace and desiccant assessment. Blisters can provide unit separation, but their barrier depends on the forming web and lidding material. Packaging also has to accommodate tablet count, dimensions, abrasion risk and consumer use.
Shelf life should be supported with the final formulation in the intended market pack. A stable raw material does not prove a stable compressed product.
Manufacturing pathway
A typical pathway is:
product requirement → material characterization → formulation route selection → laboratory blends or granules → compression trials → core testing → coating development if needed → packaging trials → stability → scale-up and process qualification → commercial release.
At scale, feed-frame behaviour, press speed, dwell time, compression force and ejection can expose risks that are not obvious from hand-made tablets. In-process controls usually include weight and physical attributes; the exact release plan depends on the product and market.
When tablets may be the wrong format
Reconsider the format when the dose creates an unacceptable tablet size or count, the active cannot tolerate the proposed process, the blend cannot be made to compress reliably without disproportionate complexity, or the intended user cannot comfortably swallow the unit.
Capsules, powders, liquids, gummies or oral films solve different product problems. Format selection should follow the dose, ingredient behaviour, use experience, stability and commercial pathway—not familiarity alone.
Sources and evidence boundaries
- Portier, Vervaet and Vanhoorne, “Continuous Twin Screw Granulation: A Review of Recent Progress and Opportunities in Formulation and Equipment Design,” Pharmaceutics 13 (2021): 668. Full text
- Peddapatla et al., “Process Model Approach to Predict Tablet Weight Variability for Direct Compression Formulations at Pilot and Production Scale,” Pharmaceutics 13 (2021): 1033. Full text
- Markl and Zeitler, “A Review of Disintegration Mechanisms and Measurement Techniques,” Pharmaceutical Research 34 (2017): 890–917. Full text
- ICH, “Q8(R2) Pharmaceutical Development.” Official guideline
The sources establish formulation/process relationships and testing concepts. They do not supply a universal formula, compression force, hardness, friability or disintegration specification for supplements.